Giovanni Caforio
Board Member
Stryker Corp (SYK)Equibles does not estimate personal net worth.
Get an email with a short summary when Stryker Corp publishes a filing, an earnings call transcript or a press release.
Get SYK alertsAbout Giovanni Caforio
Giovanni Caforio is recorded as Board Member at Stryker Corp (SYK). The newest filing on record that lists Giovanni Caforio as Board Member at Stryker Corp (SYK) is dated March 23, 2026. Earlier roles on record: CEO at Bristol Myers Squibb Co (BMY) until November 1, 2023. Bristol Myers Squibb Co reported in an 8-K filed April 26, 2023 that Giovanni Caforio retired as Chief Executive Officer, effective November 1, 2023. Giovanni Caforio has spoken on 15 earnings calls across 1 company, most recently for Bristol Myers Squibb Co on October 26, 2023. Stryker Corp is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Giovanni Caforio spoke on are classified in the Healthcare sector. Other leadership on record at Stryker Corp includes Spencer S. Stiles (CEO and Board Member), Kevin A. Lobo (Chairman and Board Member), Preston W. Wells (CFO) and 7 others.
“Dr. Caforio will continue to serve as Chairman of the Board until he retires as CEO on November 1, 2023, and after that will serve as Executive Chairman of the Board for a transition period to be determined by the Board.”
Giovanni Caforio on recent calls
“We delivered sales growth for our in-line and new product portfolios and continued to advance the renewal of our business, delivered important clinical and regulatory milestones, and further strengthened the long-term prospects of the company through the planned acquisition of Mirati.”
“Starting on Slide 4, as you will have seen in our press release this morning, today we updated our outlook for 2023. The updates were driven by a significant change in our expectations for Revlimid and to a lesser extent Pomalyst for the year.”
“Before we discuss our first quarter results, I'd like to address the leadership transition plan we announced yesterday. After 23 years at Bristol-Myers Squibb, including the last 8 as CEO, I have decided to retire as CEO effective November 1, 2023.”
“I am pleased to report another strong quarter for Bristol-Myers Squibb, concluding a very successful year. Last year was an important year for our company, the first with Revlimid generics.”
“I'm pleased to share that we delivered another good quarter, and we continue to advance our strategy to position Bristol-Myers Squibb for sustainable growth.”
Affiliation history
-
Current
Start not stated–present
Last confirmed March 23, 2026
-
Start not stated–2023-11-01
-
Start not stated–2023-11-01
Company network
Drug Manufacturers - General · Healthcare
CEO
Leadership on record at Stryker Corp
- Spencer S. Stiles CEO, Board Member
- Kevin A. Lobo Chairman, Board Member
- Preston W. Wells CFO
- Preston Wells CFO
- Spencer Stiles COO
- Timothy J. Scannell COO
- Emily Baculik Chief Accounting Officer
- Andrew K. Silvernail Board Member
- Emmanuel P. Maceda Board Member
- Giovanni Caforio, M.D. Board Member